ABEO ▲ +1.4% - Abeona Therapeutics Inc.
$ABEO - Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
Abeona Therapeutics rose 1.4% following Ultragenyx's U.S. FDA approval of FAYUVI, a gene therapy for Sanfilippo Syndrome Type A. The approval validates the therapeutic approach in a rare genetic disorder and may signal positive momentum for the broader gene therapy sector in which Abeona operates.
18-SEP-2026 07:30 AM ET
Share this post
More filings for $ABEO
ABEO - Abeona Therapeutics Inc. - SEC Filing Update (16-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 16, 2026ABEO - Abeona Therapeutics Inc. - SEC Filing Update (13-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 14, 2026ABEO - Abeona Therapeutics Inc. - SEC Filing Update (12-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 12, 2026ABEO ▲ +2.8% - Abeona Therapeutics Inc.Nov 10, 2026ABEO ▼ -4.1% - Abeona Therapeutics Inc.Nov 9, 2026ABEO ▲ +3.8% - Abeona Therapeutics Inc.Nov 9, 2026
View full $ABEO filing history →💬 Comments
Loading comments…
Leave a comment
